The US Food and Drug Administration (FDA) has altered the usage labels on two cancer drugs on the basis of a re-evaluation of clinical data.
at the Dana-Farber Cancer Institute in Boston, Massachusetts, and another ODAC member, says future calls for retrospective analyses will probably be considered on a case-by-case basis. "It was the striking nature of the data that led to the recommendation" to change Erbitux and Vectibix labelling, he says, "and it's unlikely to happen very often in the future".
Indeed, many argue that the conditions surrounding the label change were unique and won't set a precedent. 
